# A Study to Evaluate Pazopanib as an Adjuvant Treatment for Localized Renal Cell Carcinoma (RCC)

> **NCT01235962** · PHASE3 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 1538 (actual)

## Conditions studied

- Renal Cell Carcinoma (RCC)
- Cancer

## Interventions

- **DRUG:** pazopanib
- **DRUG:** placebo
- **DRUG:** pazopanib
- **DRUG:** placebo

## Key facts

- **NCT ID:** NCT01235962
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-11-30
- **Primary completion:** 2015-10-15
- **Final completion:** 2019-04-15
- **Target enrollment:** 1538 (ACTUAL)
- **Last updated:** 2020-11-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01235962

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01235962, "A Study to Evaluate Pazopanib as an Adjuvant Treatment for Localized Renal Cell Carcinoma (RCC)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01235962. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*